



American Medical Association
515 North State Street
Chicago, Illinois 60610

Telefax: 312-464-4028
sophia_fuerst@ama-assn.org

September 10, 2001

SOPHIA V. FUERST, Director
312-464-4045

Jeffrey R. Bernstein, Ph.D.
Director of Strategic Planning
WINSTON Laboratories, Inc.
100 Fairway Drive, Suite 134
Vernon Hills, Illinois 60061

Dear Dr. Bernstein:

I am writing to inform you of the results of the USAN Council's reconsideration of the USAN, "zucapsaicin" for cis-8-methyl,-N-vanillyl-6-nonenamide, which occurred during the USAN Council's summer meeting on June 29, 2001 in Rockville, Maryland.

The Council was presented with the historical background of events and rationale associated with the selection of the USAN "zucapsaicin" for the compound above and WINSTON's request with accompanying documentation that the USAN be rescinded and "civamide" be adopted as the USAN.

The USAN Council has denied WINSTON's request and has chosen to support retaining the official USAN "zucapsaicin", adopted in 1993.

As stated in earlier correspondence, should WINSTON decide to appeal the USAN decision, the USAN Council has established the USAN Review Board to conduct such procedure. Dr. Joel Bernstein's letter to Mr. Joseph G. Valentino, USAN Review Board Secretary, dated January 10, 2000, indicated a willingness to pursue the USAN appeals process. For your convenience, I enclose a copy of the USAN Review Board, Rules of Procedure with this letter. Please contact me if you have any further question regarding this matter.

Sincerely yours,

Sophia V. Fuerst
Director, USAN Program

Attachment

cc: Alice J. Matuszak, Ph.D. Lucinda Maine, PhD.
Joseph G. Valentino, J.D. Thomas P. Healy, Jr., J.D.
Roger L. Williams, M.D.